Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Liver Metastases

Liver Metastases

Subtypes of Liver Metastases

Colorectal liver metastases 3 Gastric cancer with liver metastases 1 Liver oligometastases 0

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Liver Metastases

18 trials tracked for Liver Metastases: 1 in phase 3 or 4.

18Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 1 Phase 2 10 Phase 1 1 Other / NA 6
  1. Phase 3 Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases Completed
  2. Phase 2 Low Dose ICG for Biliary Tract and Tumor Imaging Completed
  3. Phase 2 Treatment of Liver Metastases With Electrochemotherapy Completed
  4. Phase 2 Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Completed
  5. Phase 2 Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 Completed
  6. Phase 2 Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II Completed
Show 12 more trials
  1. Phase 2 Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma Completed
  2. Phase 2 Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery Completed
  3. Phase 2 Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease Completed
  4. Phase 2 Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases Completed
  5. Phase 2 Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers Completed
  6. Phase 1 A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases Completed
  7. N/A Stereotactic Body Radiation Therapy (SBRT) for Liver Mets Completed
  8. N/A Individualized Stereotactic Body Radiotherapy of Liver Metastases Completed
  9. N/A Stereotactic Body Radiotherapy for Liver Tumors Completed
  10. N/A Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases Completed
  11. N/A Study to Evaluate VORTX Rx (Theresa) Completed
  12. N/A FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer Completed

Showing the 18 most-cited and recently-updated of 18 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis finds R1 vascular margin acceptable for HCC but not CLM in minimally invasive liver surgery
Gastroenterology Meta-analysis
Meta-analysis finds R1 vascular margin acceptable for HCC but not CLM in minimally invasive liver surgery Tumor margin choice matters differently for liver cancer types
This meta-analysis of 839 patients undergoing minimally invasive liver surgery found that R1 vascular margin (R1v) hepatectomy yields local …
For liver cancer, leaving a narrow margin is safe. For colorectal metastases, it raises recurrence risk.
May 1, 2026
SBRT with ≥70 Gy BED10 for colorectal liver metastases shows 74.5% 1-year FFLP
Oncology Cohort
SBRT with ≥70 Gy BED10 for colorectal liver metastases shows 74.5% 1-year FFLP Can a higher radiation dose improve tumor control in liver metastases?
This retrospective cohort study of 116 patients with colorectal liver metastases treated with stereotactic body radiation therapy (SBRT) fou…
For liver cancer spread from colorectal cancer, higher radiation doses to tumors significantly lower the risk of regrowth, while multiple tu…
Frontiers Apr 19, 2026
Serplulimab with FOLFOX showed disease control in AFP-producing gastric adenocarcinoma with liver metastases
Allergy & Immunology Cohort
Serplulimab with FOLFOX showed disease control in AFP-producing gastric adenocarcinoma with liver metastases Rare Stomach Cancer Shrinks After New Combo Treatment
This case report and literature review describes a 67-year-old man with AFP-producing gastric adenocarcinoma and liver metastases treated wi…
A rare stomach cancer that spread to the liver shrank dramatically when doctors combined standard chemotherapy with a newer immune-boosting …
Frontiers Apr 16, 2026
Minimally invasive surgical thermal ablation shows improved technical success and safety in liver malignancy patients
Oncology Meta-analysis
Minimally invasive surgical thermal ablation shows improved technical success and safety in liver malignancy patients Minimally invasive surgery offers safe, effective treatment for liver cancer tumors
This systematic review and meta-analysis evaluated 3983 patients with hepatocellular carcinoma or colorectal liver metastases treated with m…
Minimally invasive surgery safely destroys liver cancer tumors with just 1% failure rate and 0.25% death risk for patients who can't have fu…
Apr 14, 2026
Robotic simultaneous resection for synchronous colorectal cancer and liver metastases shows feasibility and safety in a meta-analysis
Gastroenterology Meta-analysis
Robotic simultaneous resection for synchronous colorectal cancer and liver metastases shows feasibility and safety in a meta-analysis Robots Are Removing Colon Cancer and Liver Tumors in One Operation
This single-arm meta-analysis included 165 patients aged 18 or older with synchronous colorectal cancer and liver metastases.
Robotic surgery safely removes colon cancer and liver tumors in one operation, sparing some patients a second major procedure.
Apr 14, 2026
Phase II RCT finds no OS benefit for hepatectomy in colorectal cancer with liver and lung metastases
Gastroenterology RCT
Phase II RCT finds no OS benefit for hepatectomy in colorectal cancer with liver and lung metastases Does removing liver tumors help when lung tumors remain? A small trial offers mixed answers
A phase II randomized trial in 27 patients with colorectal adenocarcinoma and resectable liver/unresectable lung metastases compared hepatec…
A small trial stopped early found no survival benefit for liver surgery when lung tumors remain, yet patients who actually got the operation…
Apr 3, 2026